Last reviewed · How we verify
Antithrombin III
Antithrombin III is a natural anticoagulant protein that inhibits blood clotting factors (thrombin and factor Xa) to prevent pathological thrombosis.
Antithrombin III is a natural anticoagulant protein that inhibits blood clotting factors (thrombin and factor Xa) to prevent pathological thrombosis. Used for Antithrombin III deficiency (congenital or acquired) for prevention and treatment of thromboembolism, Perioperative thromboembolism prophylaxis in patients with antithrombin deficiency.
At a glance
| Generic name | Antithrombin III |
|---|---|
| Also known as | Thrombate III, Thrombate, Anbinex, ATIII |
| Sponsor | Octapharma |
| Drug class | Anticoagulant; plasma-derived protease inhibitor |
| Target | Thrombin (Factor IIa); Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Hematology |
| Phase | FDA-approved |
Mechanism of action
Antithrombin III is a serine protease inhibitor that circulates in blood and binds to and inactivates thrombin (factor IIa) and factor Xa, key enzymes in the coagulation cascade. This prevents excessive clot formation. The drug is derived from human plasma and is used as a replacement therapy in patients with antithrombin deficiency, either congenital or acquired, to restore anticoagulant capacity.
Approved indications
- Antithrombin III deficiency (congenital or acquired) for prevention and treatment of thromboembolism
- Perioperative thromboembolism prophylaxis in patients with antithrombin deficiency
Common side effects
- Dizziness
- Nausea
- Chest pain
- Infusion site reactions
- Allergic reactions
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B (PHASE3)
- Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (PHASE3)
- Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass (PHASE3)
- Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia
- Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)
- Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
- Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |